Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ulrich Costabel

Showing results (121-130 of 200) with videos related to

Pageof 20
Sort By:
Respiratory Medicine|September 22, 2012
Different MUC1 gene polymorphisms in German and Japanese ethnicities affect serum KL-6 levelsYasushi Horimasu, Noboru Hattori, Nobuhisa Ishikawa, et al.
Respiratory Research|April 8, 2022
Safety and tolerability of nintedanib in patients with progressive fibrosing interstitial lung diseases: data from the randomized controlled INBUILD trialVincent Cottin, Fernando J Martinez, R Gisli Jenkins, et al.
Thorax|October 11, 2017
Long-term treatment of patients with idiopathic pulmonary fibrosis with nintedanib: results from the TOMORROW trial and its open-label extensionLuca Richeldi, Michael Kreuter, Moisés Selman, et al.
The European Respiratory Journal|July 30, 2016
Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung functionCarlo Albera, Ulrich Costabel, Elizabeth A Fagan, et al.
American Journal of Respiratory and Critical Care Medicine|July 5, 2003
Clinical diagnosis of hypersensitivity pneumonitisYves Lacasse, Moises Selman, Ulrich Costabel, et al.
Respirology (Carlton, Vic.)|May 20, 2014
Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosisDominique Valeyre, Carlo Albera, Williamson Z Bradford, et al.
Advances in Therapy|June 30, 2023
Efficacy and Safety of Pirfenidone in Advanced Versus Non-Advanced Idiopathic Pulmonary Fibrosis: Post-Hoc Analysis of Six Clinical StudiesJürgen Behr, Steven D Nathan, Ulrich Costabel, et al.
International Archives of Allergy and Immunology|January 8, 2009
Classification of hypersensitivity pneumonitis: a hypothesisYves Lacasse, Moises Selman, Ulrich Costabel, et al.
Respiratory Research|November 11, 2024
Serum soluble isoform of receptor for advanced glycation end product is a predictive biomarker for acute exacerbation of idiopathic pulmonary fibrosis: a German and Japanese cohort studyErika Kitadai, Kakuhiro Yamaguchi, Shinichiro Ohshimo, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|May 19, 2012
Localization of propionibacterium acnes in granulomas supports a possible etiologic link between sarcoidosis and the bacteriumMariko Negi, Tamiko Takemura, Josune Guzman, et al.
Pageof 20

Showing results (121-130 of 200) with videos related to

Sort By:
Pageof 20
Respiratory Medicine|September 22, 2012
Different MUC1 gene polymorphisms in German and Japanese ethnicities affect serum KL-6 levelsYasushi Horimasu, Noboru Hattori, Nobuhisa Ishikawa, et al.
Respiratory Research|April 8, 2022
Safety and tolerability of nintedanib in patients with progressive fibrosing interstitial lung diseases: data from the randomized controlled INBUILD trialVincent Cottin, Fernando J Martinez, R Gisli Jenkins, et al.
Thorax|October 11, 2017
Long-term treatment of patients with idiopathic pulmonary fibrosis with nintedanib: results from the TOMORROW trial and its open-label extensionLuca Richeldi, Michael Kreuter, Moisés Selman, et al.
The European Respiratory Journal|July 30, 2016
Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung functionCarlo Albera, Ulrich Costabel, Elizabeth A Fagan, et al.
American Journal of Respiratory and Critical Care Medicine|July 5, 2003
Clinical diagnosis of hypersensitivity pneumonitisYves Lacasse, Moises Selman, Ulrich Costabel, et al.
Respirology (Carlton, Vic.)|May 20, 2014
Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosisDominique Valeyre, Carlo Albera, Williamson Z Bradford, et al.
Advances in Therapy|June 30, 2023
Efficacy and Safety of Pirfenidone in Advanced Versus Non-Advanced Idiopathic Pulmonary Fibrosis: Post-Hoc Analysis of Six Clinical StudiesJürgen Behr, Steven D Nathan, Ulrich Costabel, et al.
International Archives of Allergy and Immunology|January 8, 2009
Classification of hypersensitivity pneumonitis: a hypothesisYves Lacasse, Moises Selman, Ulrich Costabel, et al.
Respiratory Research|November 11, 2024
Serum soluble isoform of receptor for advanced glycation end product is a predictive biomarker for acute exacerbation of idiopathic pulmonary fibrosis: a German and Japanese cohort studyErika Kitadai, Kakuhiro Yamaguchi, Shinichiro Ohshimo, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|May 19, 2012
Localization of propionibacterium acnes in granulomas supports a possible etiologic link between sarcoidosis and the bacteriumMariko Negi, Tamiko Takemura, Josune Guzman, et al.
Pageof 20